In a bold display of confidence, General Motors (GM) announced a substantial 25% increase in its quarterly dividend, pushing the payout to 15 cents per share. This strategic shift is not only a response to current market pressures but also a direct challenge to its main competitor, Ford Motor Company, which had previously matched GM’s
Business
Eli Lilly is shifting the landscape of obesity treatment with its aggressive pricing strategy for Zepbound, a weight loss drug that has garnered significant attention. Recently, the company introduced higher doses of Zepbound in single-dose vials at substantially reduced prices aimed at those lacking insurance coverage. This shift is not only a compelling business strategy
Jamie Dimon, the outspoken CEO of JPMorgan Chase, has again stirred the pot by suggesting that the current U.S. government is bloated and inefficient. In a candid interview, he articulated a viewpoint that resonates with many disillusioned citizens: the bureaucratic machinery is riddled with waste, incompetence, and a lack of accountability. This critique isn’t merely